Table 1 Clinical-pathological characteristics of patients at diagnosis
From: Effect of neoadjuvant therapy on breast cancer biomarker profile
N (%) | |
|---|---|
Clinical stage | |
I (I, Ia, Ib) | 11 (7.9) |
II (IIa, IIb) | 57 (41.0) |
III (IIIa, IIIb, IIIc) | 69 (49.6) |
IV | 2 (1.4) |
Scarff-Bloom Richardson | |
I | 10 (7.2) |
II | 83 (59.7) |
III | 46 (33.1) |
Invasion | |
Yes | 64 (46.0) |
No | 55 (39.6) |
Unknown | 20 (14.4) |
Type of invasion | |
Lympho-vascular | 38 (45.2) |
Dermal | 6 (7.1) |
Lympho-vascular and perineural | 9 (10.7) |
Dermal lymphatic | 5 (6.0) |
Perineural | 4 (4.8) |
Dermal lymphatic and perineural | 1 (1.2) |
Dermal and perineural | 1 (1.2) |
Unknown | 20 (23.8) |
Axillary lymph node dissection | |
Yes | 113 (81.3) |
No | 26 (18.7) |
Involvement of lymph nodes | |
Yes | 67 (59.3) |
No | 46 (40.7) |
NAT administration | |
Yes | 78 (56.1) |
No | 61 (43.9) |
Type of NAT scheme | |
Hormonal | 6 (7.7) |
Cytotoxic | 56 (71.8) |
Cytotoxic + trastuzumab | 11 (14.1) |
Combined (hormonal+ cytotoxic) | 5 (6.4) |